

FILSPARI® (sparsentan)

Acute Kidney Injury

Summary

Prescribing Information

- FILSPARI is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression¹
- In the PROTECT trial, acute kidney injury occurred in 12 (6%) patients treated with FILSPARI compared to 5 (2%) patients treated with irbesartan¹
- Monitor kidney function periodically. Drugs that inhibit the renin-angiotensin system can cause acute kidney injury¹
- Patients whose kidney function may depend in part on the activity of the renin-angiotensin system (eg, patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute kidney injury on FILSPARI¹
- Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in kidney function while on FILSPARI¹

Background

- Sparsentan is a novel, first-in-class, and the only single molecule antagonist of the ET_A and AT₁ receptors²⁻⁴

Study Data

- In the PROTECT study⁵:
 - TEAEs of AKI occurred in 12 (6%) patients taking sparsentan and 5 (2%) patients taking irbesartan
 - Serious TEAEs of AKI occurred in 4 (2%) patients taking sparsentan and 1 (<1%) patient taking irbesartan
 - Treatment discontinuations due to AKI occurred in 3 (1%) taking sparsentan and none taking irbesartan
- Reports of AKI in the PROTECT study were based on changes in serum creatinine between study visits rather than an acute hospital setting, and may reflect a gradual decline in kidney function rather than AKI⁶

Prescribing Information

- In the PROTECT trial, acute kidney injury occurred in 12 (6%) FILSPARI-treated patients compared to 5 (2%) irbesartan-treated patients¹
- Monitor kidney function periodically. Drugs that inhibit the renin-angiotensin system can cause acute kidney injury¹
- Patients whose kidney function may depend in part on the activity of the renin-angiotensin system (eg, patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute kidney injury on FILSPARI¹
- Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in kidney function while on FILSPARI¹

For more information, please refer to the Prescribing Information.

Background

Sparsentan is a novel, first-in-class, and the only single molecule antagonist of the ET_A and AT₁ receptors.²⁻⁴ Preclinical studies in rodent models of chronic kidney disease have shown that blockade of both ET_A and AT₁ pathways reduces proteinuria, protects podocytes, and prevents glomerulosclerosis and mesangial cell proliferation.⁷⁻⁹

The PROTECT Study

The PROTECT study ([NCT03762850](#)) is a phase 3, global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating long-term antiproteinuric and nephroprotective efficacy and safety of 400 mg of sparsentan in patients with IgA nephropathy compared to 300 mg of irbesartan.¹⁰ The study includes 404 patients ages 18 years and older with biopsy proven IgA nephropathy who experience persistent proteinuria despite available ACEi or ARB therapy. Patients with urine protein ≥ 1 g/day at screening, eGFR ≥ 30 mL/min/1.73 m², SBP ≤ 150 mm Hg, and DBP ≤ 100 mm Hg were eligible.¹¹ The PROTECT study protocol provides for an unblinded interim analysis of at least 280 patients to be performed after 36 weeks of treatment to evaluate the primary efficacy endpoint, defined as change in proteinuria (UPCR) at Week 36 from baseline. Secondary efficacy endpoints include the rate of change in eGFR following the initiation of randomized treatment over 58-week and 110-week periods, as well as rate of change in eGFR over 52-week and 104-week periods following the first 6 weeks of randomized treatment.^{11,12} The PROTECT study also examines change from baseline in UACR based on a 24-hour urine sample at Week 36, and prespecified exploratory endpoints of complete (UPE < 0.3 g/day) and partial (UPE < 1.0 g/day) proteinuria remission at least once at any time during the double-blind period. In addition, this study evaluates the proportion of patients in each group reaching a confirmed 40% reduction in eGFR from baseline, KF, or all-cause mortality. KF is defined as initiation of KRT or sustained eGFR value of < 15 mL/min/1.73 m².⁶ Reduction in proteinuria and decline in rate of eGFR are largely accepted as surrogate markers of treatment effect in studies of KF.^{6,13}

Study Data

The PROTECT Study

While Kidney Disease Improving Global Outcomes (KDIGO) guidelines provide criteria for diagnosing AKI, reports of AKI adverse events in sparsentan studies may have been based on elevations in serum creatinine between study visits. KDIGO guidelines for diagnosing AKI are as follows¹⁴:

- Increased serum creatinine ≥ 0.3 mg/dL (≥ 26.5 $\mu\text{mol/L}$) within 48 hours; or
- Increased serum creatinine $\geq 1.5\times$ baseline (which is known or presumed to have occurred within the prior 7 days); or
- Urine volume < 0.5 mL/kg/hour for 6 hours or more

While these KDIGO guidelines were described in the study protocol, they were designed for hospital settings where baseline values within given timeframes (ie, the preceding 48 hours to 7 days) are available. However, in interventional studies such as PROTECT, conducted in the outpatient setting with visits typically 12 weeks apart, repeat values across a shorter timeframe were not available in most cases. In such instances, at the investigator's discretion and based on the guidance provided in the protocol, reports of AKI were typically based on serum creatinine changes between study visits, which were several weeks apart. Changes in serum creatinine may therefore have been more reflective of gradual decreases in kidney function instead of clinical AKI.⁶

2-Year Safety Data

Over 2 years of treatment, TEAEs occurred in 187 (93%) patients taking sparsentan and 177 (88%) patients in the irbesartan group. AKI occurred in 12 (6%) and 5 (2%) patients in the sparsentan and irbesartan groups, respectively. Among sparsentan patients experiencing AKI, 4 (2%) were considered serious vs 1 ($< 1\%$) patient taking irbesartan. Three patients in the sparsentan group discontinued treatment due to AKI; there were no AKI-related discontinuations in the irbesartan group.⁵

PROTECT OLE

In the PROTECT OLE, among patients receiving concomitant sparsentan and SGLT2 inhibitor treatment (N=61), a serious TEAE of AKI was reported in 1 (2%) patient.¹⁵

AKI in Additional Clinical Trials

The DUPLEX Study

The DUPLEX study ([NCT03493685](#)) is a global, randomized, multicenter, double-blind, active-controlled, phase 3 trial examining the safety and efficacy of sparsentan as compared to irbesartan in patients aged 8 to 75 years with biopsy-proven FSGS. Over 108 weeks of treatment, 172 (93.5%) patients in the sparsentan group and 174 (93%) patients in the irbesartan group reported at least 1 AE. AKI was reported in 8 (4.3%) patients taking sparsentan and 13 (7.0%) taking irbesartan. AKI was considered serious in 3 (1.6%) and 8 (4.3%) patients in the sparsentan and irbesartan groups, respectively.¹⁶

The EPPIK Study

The EPPIK study ([NCT05003986](#)) is a phase 2, global, open-label, single-arm, multicenter cohort study to evaluate the safety, efficacy, and PK of a liquid formulation of sparsentan in pediatric patients with selected proteinuric glomerular diseases. The primary objective of the EPPIK study is to examine long-term antiproteinuric and nephroprotective potential and safety in this pediatric population.¹⁷ Over 12 weeks of sparsentan treatment, 1 patient experienced a serious TEAE of AKI.¹⁸

The SPARTACUS Study

SPARTACUS ([NCT05856760](#)) is an open-label, multicenter, single-arm exploratory phase 2 trial investigating the safety and efficacy of up to 24 weeks of sparsentan added to a stable dose of SGLT2 inhibitors in patients with IgA nephropathy at risk of disease progression. Among SPARTACUS patients (N=20), AKI was reported as a serious TEAE in 1 patient. The event was mild and unrelated to either sparsentan or SGLT2 inhibitor treatment, and resolved upon interruption of combination therapy.¹⁹

Abbreviations

ACEi, angiotensin-converting enzyme inhibitor; AE, adverse event; AKI, acute kidney injury; ARB, angiotensin receptor blocker; AT₁, angiotensin II type 1; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ET_A, endothelin-1 type A; FSGS, focal segmental glomerulosclerosis; IgA, immunoglobulin A; KF, kidney failure; KRT, kidney replacement therapy; OLE, open-label extension; PK, pharmacokinetics; SBP, systolic blood pressure; SGLT2, sodium-glucose cotransporter-2; TEAE, treatment-emergent adverse event; UACR, urine albumin-to-creatinine ratio; UPCR, urine protein-to-creatinine ratio; UPE, urinary protein excretion.

References

1. FILSPARI. Prescribing information. Traverre Therapeutics Inc; September 2024.
2. Komers R, Gipson DS, Nelson P, et al. Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: Randomized, controlled trial design (DUET). *Kidney Int Rep.* 2017;2(4):654-664. doi:10.1016/j.ekir.2017.02.019
3. Raczynska A, Pawlowicz-Szlarska E, Nowicki M. Sparsentan—a dual antagonist—literature review on endothelin and endothelin antagonists. *Nephrol Dial Pol.* 2021;25:77-82.
4. Trachtman H, Nelson P, Adler S, et al. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. *J Am Soc Nephrol.* 2018;29(11):2745-2754. doi:10.1681/ASN.2018010091
5. Rovin B, Barratt J, Heerspink HJ, et al. Efficacy and safety of sparsentan vs irbesartan in patients with IgA nephropathy: 2-year results from PROTECT, a phase 3 randomized active-

Summary	PI	Background	Study Data	Abbreviations	References
---------	----	------------	------------	---------------	------------

controlled clinical trial. *Lancet*. 2023;402(10417):2077-2090. doi:10.1016/S0140-6736(23)02302-4

6. Heerspink HJ, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised double-blind active-controlled clinical trial. *Lancet*. 2023;401(10388):1584-1594. doi:10.1016/S0140-6736(23)00569-X
7. Nagasawa H, Suzuki H, Jenkinson C, et al. The dual endothelin type A receptor (ET_AR) and angiotensin II type 1 receptor (AT₁R) antagonist, sparsentan, protects against the development of albuminuria and glomerulosclerosis in the gddY mouse model of IgA nephropathy. Poster presented at: ERA-EDTA Virtual Congress; June 6-9, 2020; Virtual Meeting.
8. Nagasawa H, Suzuki H, Jenkinson C, et al. Sparsentan, the dual endothelin angiotensin receptor antagonist (DEARA), attenuates albuminuria and protects from the development of renal injury to a greater extent than losartan in the gddY mouse model of IgA nephropathy: A 16-week study. Mini oral presented at: ERA-EDTA Congress; May 19-22, 2022; Paris, France.
9. Bedard P, Jenkinson C, Komers R. Sparsentan protects the glomerular basement membrane and glycocalyx, and attenuates proteinuria in a rat model of focal segmental glomerulosclerosis (FSGS). Abstract presented at: ERA-EDTA Congress; May 19-22, 2022; Paris, France.
10. Barratt J, Rovin B, Wong MG, et al. IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study. *Kidney Int Rep*. 2023;1-14. doi:10.1016/j.ekir.2023.02.1086
11. Barratt J, Rovin B, Diva U, Mercer A, Komers R, PROTECT Study Design Group. Supplementary material: Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial). *Kidney Int Rep*. 2019;4(11):1633-1637. doi:10.1016/j.ekir.2019.08.007
12. Wong M, Barratt J, Komers R, Mercer A, Rosenberg N. Baseline characteristics of adults enrolled in the ongoing phase 3 randomized, double-blind, active-control trial of sparsentan for the treatment of immunoglobulin A nephropathy (PROTECT). Mini Oral presented at: ERA-EDTA Congress; May 19-22, 2022; Paris, France.
13. Thompson A, Carroll K, Inker LA, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. *Clin J Am Soc Nephrol*. 2019;14(3):469-481. doi:10.2215/CJN.08600718
14. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. *Kidney Int*. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021
15. Kooienga L, Malecki R, Preciado P, Nandola H, Mercer A. Concomitant sparsentan (SPAR) and sodium-glucose cotransporter-2 inhibitors (sglt2is) in patients with IgA nephropathy (IgAN) in the PROTECT open-label extension (OLE). Poster presented at: ASN Kidney Week; October 23-27, 2024; San Diego, CA.
16. Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. *N Engl J Med*. 2023;389(26):2436-2445. doi:10.1056/NEJMoa2308550

17. Trachtman H, Saleem M, Coppo R, Rheault MN, He P, Komers R. Sparsentan for treatment of pediatric patients with selected proteinuric glomerular diseases: Design of the phase 2 EPPIK study. Poster presented at: American Society of Nephrology Kidney Week; November 4-7, 2021; San Diego, California.
18. Trachtman H, Coppo R, Ahmed NAM, et al. Sparsentan in pediatric patients with rare proteinuric kidney disease: Preliminary findings from the EPPIK study. Poster presented at: ASN Kidney Week; October 23-27, 2024; San Diego, CA.
19. Ayoub I, Tang S, Kooienga L, et al. Concomitant sparsentan and sodium-glucose cotransporter-2 inhibitors in adults with IgA nephropathy in the ongoing phase 2 SPARTACUS trial. Poster presented at: ASN Kidney Week; October 24-27, 2024; San Diego, CA.